Mirum Pharmaceuticals’ Livmarli secures FDA nod to treat cholestatic pruritus
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Mar 24
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…
13 Mar 24
The collaboration will initially focus on the discovery and development of biologic therapies for the treatment of cancer…
13 Mar 24
Under the partnership, Dassault Systèmes, a science-based firm with virtual twin experiences, and CDR-Life will study the stability…
13 Mar 24
The Cell Shuttle is an automated, ultra-high throughput, manufacturing platform designed to address the global patient demand while…
13 Mar 24
GV20 Therapeutics will leverage the resources provided by NVIDIA Inception to develop new AI models for drug discovery,…
12 Mar 24
The global collaboration and exclusive option-to-license agreement focuses on novel G protein-coupled receptor (GPCR) targets to improve patient…
11 Mar 24
The data from FRONTIER 2, the long-term extension to Phase 2b FRONTIER 1 study, showed that JNJ-2113 resulted…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Mar 24
The approval was based on Wegovy's efficacy and safety results from the SELECT cardiovascular outcomes study in which…
08 Mar 24
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was…
06 Mar 24
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…